Variability of definition of high‐risk multiple myeloma across phase III clinical trials

The definition of high‐risk multiple myeloma (HRMM) is evolving. Use of a clear definition of HRMM in clinical trials was not previously studied. We explored the definition of HRMM in completed phase III clinical trials. There is extreme variability in the definition and cutoffs used to define HRMM,...

Descripción completa

Detalles Bibliográficos
Autores principales: Abu Za'nouneh, Faris Jamal, Ababneh, Obada, Schinke, Carolina, Thanendrarajan, Sharmilan, Zangari, Maurizio, Shaughnessy, John D., Zhan, Fenghuang, van Rhee, Frits, Al Hadidi, Samer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188470/
https://www.ncbi.nlm.nih.gov/pubmed/37206288
http://dx.doi.org/10.1002/jha2.675

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188470/
https://www.ncbi.nlm.nih.gov/pubmed/37206288
http://dx.doi.org/10.1002/jha2.675

Ejemplares similares